Placeholder Banner

Letter to Governor Deval Patrick

March 10, 2016

RE: Concerns with Senate Bill 2863

Dear Governor Patrick,

On behalf of the more than 1,200 members of the Biotechnology Industry Organization (BIO), I am writing to express concerns with SB 2863 "An Act to Control Cost Containment, Transparency and Efficiency in the Delivery of Quality Health Care." This legislation, currently pending your approval, contains provisions in Section 14 of the bill that could have serious unintended consequences on the Commonwealth's biotechnology industry.

As one of the world's leading medical centers and biotechnology industry hubs, we acknowledge the need for Massachusetts to be at the forefront of implementing policies to improve health care. In addition to the Life Science Initiative, the Commonwealth Care Program is an example of a progressive effort to address a concern affecting many states - creating access to affordable health insurance for all citizens. These programs have become national models and send a clear message that Massachusetts is serious about promoting life science innovation and improving access to quality health care.


Download Full Comments Below
Read the letter
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…